Additional Practice-informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study of Adagrasib (MRTX849) in Patients With KRASG12C-mutated Non--Small Cell Lung Cancer...Academy of Oncology Nurse & Patient Navigators (AONN+) 14th Annual Navigation & Survivorship Conference, November 15–19, 2023, San Antonio, Texas.

Background: Adagrasib, a KRASG12C inhibitor selected for favorable properties, including a long half-life (23 hr), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration, has demonstrated clinical activity in patients with KRASG12C-mutated non--small cell lung cancer (NSCLC) w...

Descripción completa

Detalles Bibliográficos

Publicado en:	Journal of Oncology Navigation & Survivorship Vol. 14; no. 11; pp. 350 - 351
Autores principales:	Zhang, Jun, Leventakos, Konstantinos, Leal, Ticiana A., Pennell, Nathan A., Barve, Minal, Paulson, Scott, Bazhenova, Lyudmila, Johnson, Melissa L., Chao, Richard C., Velastegui, Karen, Qian, Chunlin, Spira, Alexander
Formato:	abstract proceedings research Journal Article
Publicado:	Amplity Health Nov2023
Acceso en línea:	Ver este registro en EBSCOhost